Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -891.33% is 122% below its 5-year average of -401.69%, near the high end of its 5-year range (-3422.94%–-40.33%).
43.36% above its 12-month average of -1573.66%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -116.32%.
OPERATING MARGIN
-891.33%
OPERATING MARGIN AVG TTM
-1573.66%
OPERATING MARGIN AVG 3Y
-612.27%
OPERATING MARGIN AVG 5Y
-401.69%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+43.36%
CURRENT VS 3Y AVG
-45.58%
CURRENT VS 5Y AVG
-121.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Kymera Therapeutics, Inc.
Market Cap
$8.61B
Operating Margin
-891.33%
TTM Avg
-1573.66%
3Y Avg
-612.27%
5Y Avg
-401.69%
Market Cap
$8.64B
Operating Margin
11.86%
TTM Avg
-8457.60%
3Y Avg
-4268.44%
5Y Avg
-2881.23%
Market Cap
$8.88B
Operating Margin
-343.63%
TTM Avg
-142.72%
3Y Avg
-233.94%
5Y Avg
-270.19%
Market Cap
$8.41B
Operating Margin
4.07%
TTM Avg
-1.39%
3Y Avg
-5.39%
5Y Avg
-20.02%
Market Cap
$8.95B
Operating Margin
3.61%
TTM Avg
7.20%
3Y Avg
11.56%
5Y Avg
12.63%
Market Cap
$8.95B
Operating Margin
-24.28%
TTM Avg
-49.63%
3Y Avg
-136.06%
5Y Avg
-90.71%
Market Cap
$9.22B
Operating Margin
3.61%
TTM Avg
7.20%
3Y Avg
11.56%
5Y Avg
12.63%
Market Cap
$7.95B
Operating Margin
17.05%
TTM Avg
16.38%
3Y Avg
-1949.35%
5Y Avg
-32157.96%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.61B | -891.33% | -1573.66% | -612.27% | -401.69% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.64B | 11.86% | -8457.60% | -4268.44% | -2881.23% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.88B | -343.63% | -142.72% | -233.94% | -270.19% |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 4.07% | -1.39% | -5.39% | -20.02% |
| Bruker Corporation (BRKRP)vs › | $8.95B | 3.61% | 7.20% | 11.56% | 12.63% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.95B | -24.28% | -49.63% | -136.06% | -90.71% |
| Bruker Corporation (BRKR)vs › | $9.22B | 3.61% | 7.20% | 11.56% | 12.63% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.95B | 17.05% | 16.38% | -1949.35% | -32157.96% |
| Insulet Corp. (PODD)vs › | $9.30B | 16.89% | 16.20% | 12.06% | 10.90% |
| Vaxcyte, Inc. (PCVX)vs › | $9.54B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
102.0%
Operating Margin
-891.3%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -116.32% |
| 2026-03-31 | -244.88% |
| 2025-12-31 | -3422.94% |
| 2025-09-30 | -3347.36% |
| 2025-06-30 | -736.82% |
| 2025-03-31 | -336.77% |
| 2024-12-31 | -1092.17% |
| 2024-09-30 | -1927.93% |
| 2024-06-30 | -198.54% |
| 2024-03-31 | -562.18% |
| 2023-12-31 | -40.33% |
| 2023-09-30 | -1216.35% |
| 2023-06-30 | -262.72% |
| 2023-03-31 | -478.83% |
| 2022-12-31 | -239.36% |
| 2022-09-30 | -469.92% |
| 2022-06-30 | -354.44% |
| 2022-03-31 | -383.84% |
| 2021-12-31 | -222.55% |
| 2021-09-30 | -140.82% |
| 2021-06-30 | -133.54% |
| 2021-03-31 | -70.41% |
| 2020-12-31 | -99.98% |
| 2020-09-30 | -55.62% |
| 2020-06-30 | -431.63% |
| 2020-03-31 | -328.09% |
| 2019-12-31 | -642.83% |
| 2019-09-30 | -1248.53% |
